Orion Corporation and Newel Health enter into licensing agreement for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in pain
Digital Health Global
JANUARY 29, 2024
As showcased in the ‘ VIRPI ‘ study, ODD-403 marks a statistically significant advancement in chronic pain management. The core therapy areas of our pharmaceutical R&D are oncology and pain. The study revealed a notable reduction in the Tampa Scale for Kinesiophobia scores (-4.7
Let's personalize your content